In acute myeloid leukemia (AML) a distant super enhancer was identified that drives MYC expression in a BRD4-dependent manner.10, 16 The differential downregulation of MYC upon JQ1 treatment among the NSCLC models tested may be explained by the occurrence of different enhancer landscapes with variable dependencies on BRD4 occupancy. This evidence concerns the gene MYC and non-small cell lung carcinoma.